Publicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (13)

2024

  1. GEC-ESTRO recommendations for head & neck cancer brachytherapy (interventional radiotherapy): 2nd update with focus on HDR and PDR

    Radiotherapy and Oncology, Vol. 201

  2. Status of head and neck brachytherapy in Spain in 2022

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 456-460

  3. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  2. Interventional Radiotherapy (Brachytherapy) for the Treatment of Primary Lesions in Nasal Vestibule Malignancies

    Malignancies of the Nasal Vestibule: A New Perspective on Classification, Staging, and Treatment (Springer International Publishing), pp. 135-144

  3. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2020

  1. Targeted metabolomics analyses reveal specific metabolic alterations in high-grade prostate cancer patients

    Journal of Proteome Research, Vol. 19, Núm. 10, pp. 4082-4092

2019

  1. Metabolomics contributions to the discovery of prostate cancer biomarkers

    Metabolites, Vol. 9, Núm. 3

2018

  1. Ent cobra ontology: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy)

    Journal of Contemporary Brachytherapy, Vol. 10, Núm. 3, pp. 260-266

2017

  1. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes

    Cancer Letters, Vol. 409, pp. 42-48

  2. Erratum to: Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia (Metabolomics (2017) 13:52, 10.1007/s11306-017-1194-y)

    Metabolomics

  3. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia

    Metabolomics, Vol. 13, Núm. 5

2014

  1. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1